{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["34(4)"],"submitter":["Crisafulli S"],"pubmed_abstract":["The epidemic due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has been spreading globally, raising increasing concerns. This public health emergency has triggered a race to find medications to improve the prognosis of this disease. There is currently great interest in drug repositioning to manage SARS-CoV-2 infection, that is, the evaluation of the potential benefits of a drug that has already been proven safe and effective in humans for other approved indications. As interleukin-6 (IL-6) acts as a key driver of the inflammation associated with coronavirus disease 2019 (COVID-19), IL-6 and IL-6 receptor (IL-6R) inhibition appear to be promising targets for the treatment of COVID-19 patients. It is important to critically analyze the available evidence concernin"],"journal":["BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy"],"pagination":["415-422"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7299248"],"repository":["biostudies-literature"],"pubmed_title":["Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks."],"pmcid":["PMC7299248"],"pubmed_authors":["La Corte L","Isgro V","Trifiro G","Crisafulli S","Atzeni F"],"additional_accession":[]},"is_claimable":false,"name":"Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks.","description":"The epidemic due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has been spreading globally, raising increasing concerns. This public health emergency has triggered a race to find medications to improve the prognosis of this disease. There is currently great interest in drug repositioning to manage SARS-CoV-2 infection, that is, the evaluation of the potential benefits of a drug that has already been proven safe and effective in humans for other approved indications. As interleukin-6 (IL-6) acts as a key driver of the inflammation associated with coronavirus disease 2019 (COVID-19), IL-6 and IL-6 receptor (IL-6R) inhibition appear to be promising targets for the treatment of COVID-19 patients. It is important to critically analyze the available evidence concernin","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Aug","modification":"2025-04-22T06:38:21.625Z","creation":"2020-06-25T07:30:41Z"},"accession":"S-EPMC7299248","cross_references":{"pubmed":["32557214"],"doi":["10.1007/s40259-020-00430-1"]}}